We observed two clusters of spontaneous pneumoperitoneums in extremely low birth weight infants during the use of a protocol for early dexamethasone prophylaxis (EDP) for bronchopulmonary dysplasia from 1996 to 1997. During surgery, focal small bowel perforation (FSBP) was found in eight of nine cases. A retrospective study was designed to identify risk factors for FSBP in these extremely low birth weight infants.
RESULTS:
Infants who received EDP had a relative risk of perforation that was 12.3 times that of untreated infants. Those treated with indomethacin had a risk that was comparable with that for infants who did not receive indomethacin. Infants who received both EDP and indomethacin tended to have higher rates of pneumoperitoneum than infants who received EDP alone but comprised a cohort too small for valid analysis. The pathology of surgical specimens revealed FSBP with segmental loss of the muscularis externa. There was no evidence of fungal or bacterial infection in any of the surgical specimens.
CONCLUSION:
These findings implicate EDP, but not indomethacin, as a significant risk factor for FSBP.
Focal small bowel perforation (FSBP) is a sporadic problem occurring in premature infants. It is often clinically mistaken for perforation secondary to necrotizing enterocolitis (NEC). 1 Case reports of FSBP have associated this disorder with hypoxic-ischemic injury, 2, 3 congenital absence of the muscularis externa, 4 -6 indomethacin, 7, 8 dexamethasone, 9 ,10 and candidal infection. 11 Risk factors for FSBP have also been postulated to be multifactorial. 1 Unfortunately, evidencebased research on FSBP is scant.
In late 1996 and mid 1997, two clusters of FSBP occurred in extremely low birth weight (ELBW) infants at the University of Washington Medical Center (UWMC) neonatal intensive care unit (NICU). These clusters coincided with the onset of a standardized protocol for early dexamethasone prophylaxis (EDP) in premature infants at risk for bronchopulmonary dysplasia. During the first month, four infants who received EDP required urgent surgery for pneumoperitoneum and were found to have FSBP. The EDP protocol was suspended pending review of the cases and literature.
Review of the literature failed to find any reports of FSBP occurring in clusters. Review of all neonatal surgical cases in the previous 6 months revealed two more infants with FSBP who also weighed Ͻ1001 gm. Indomethacin prophylaxis for intraventricular hemorrhage (IVH) was noted in five of these six cases. There were no incidents of pneumoperitoneum over the next 7 months while the protocol was suspended. When the protocol was restarted, two of the next three ELBW infants who received EDP developed pneumoperitoneum from FSBP. The EDP protocol was terminated. This retrospective analysis was designed to determine whether either EDP or indomethacin were independent risk factors for FSBP in ELBW infants.
METHODS
A total of 64 infants with birth weights of Ͻ1001 gm were admitted to the UWMC NICU during the 13-month study period. Seven of these infants were excluded from analysis because of early mortality in the first week of life. All seven died from complications of prematurity without evidence of gastrointestinal compromise. An additional six Original Article
infants were excluded from the analysis because they were or would have been ineligible for the EDP protocol. Of the remaining 51 infants, 49 survived until the time of discharge. The EDP protocol used at the UWMC NICU consisted of 12 days of dexamethasone administration starting within 24 hours of birth. The initial dosage was 0.25 mg/kg twice a day of intravenous (i.v.) dexamethasone for the first 3 days; then a fixed taper was implemented over the next 9 days. Two treatment groups were eligible for EDP: (1) all infants born weighing Ͻ800 gm with a gestational age of Ͻ30 weeks; and (2) all infants born weighing Ͻ1250 gm who had FIO 2 requirements of Ͼ0.30, who required assisted ventilation at 6 hours of postnatal age, and who had hyaline membrane disease by x-ray. Infants with proven infection, hyperglycemia with a blood glucose Ͼ200 mg/dl, or hypertension resulting in pharmacologic intervention were not eligible for initiation or continuation of EDP. Informed consent for inclusion of infants in the EDP protocol was not obtained during the initial treatment period. When the EDP protocol was reinstated, parents of ELBW infants were informed of a possible relationship between EDP and FSBP.
Indomethacin was administered to ELBW infants who did not have contraindications (coagulopathy, oliguria, or pre-existing IVH) as a potential means of reducing the incidence of IVH. Indomethacin therapy consisted of four doses of 0.1 mg/kg i.v. given at 12, 24, 48, and 72 hours. Indomethacin was stopped if the infant's average urine output was Ͻ1.0 ml/kg per hour and then restarted if urine output increased to Ͼ1.0 ml/kg per hour.
Nutrition for the ELBW infants was standardized at the UWMC NICU. Hyperalimentation was initiated on day 3 of life. Trophic enteral feeds were initiated on day 7 of life and advanced slowly over a minimum of 10 days until full feeds were achieved. Human milk was the preferred form of enteral nutrition, with formula used only when human milk was unavailable. Hyperalimentation was continued until full feeds were tolerated. Ranitidine was administered i.v. as part of the hyperalimentation solution. Feeding residuals were refed with the next feeding as long as they were less than half the volume of the feeding. During the study period, neither metoclopramide or cisapride were used on ELBW infants in the first 2 weeks of life.
Medical records were reviewed for all infants born weighing Ͻ1001 gm and admitted to the UWMC NICU from October of 1996 to November of 1997. Infants weighing Ͼ1000 gm were not included in the analysis because there were no surgical cases of pneumoperitoneum in infants of Ͼ1000 gm during the study period. Gastrointestinal disease was tallied in patients who required abdominal surgery or who were medically managed for NEC (i.e., if the patient had enteral feeds discontinued, received prolonged antibiotics, and was monitored by serial abdominal x-rays). All cases of pneumoperitoneum were placed on broad spectrum antibiotics and urgently taken to surgery. The diagnosis was determined by the surgeon of record. Surgical management of FSBP consisted of limited resection with either primary anastamosis or enterostomy according to the surgeon's preference. Three patients who received enterostomies did not have surgical specimens taken during their original operations (including both cases that did not receive EDP). The surgical specimens from the five patients who received primary anastamosis were sectioned and stained with hematoxylin and eosin for routine pathology. Adjacent sections were stained for fungus at the time of data review. On analysis, 51 patients were divided into treated and untreated cohorts for dexamethasone and again for indomethacin. Gastrointestinal and postnatal outcomes were analyzed using either Student's t-test for nominal data or the -squared analysis for categorical data to look for significant differences. The relative risks and confidence intervals for FSBP were calculated for EDP and indomethacin.
RESULTS
A comparison of patient characteristics and clinical courses for EDP and indomethacin-treated infants is shown in Table 1 . Comparable prenatal and perinatal risk factors for a hypoxic or ischemic effect on the bowel were found (i.e., comparable birth weights, gestational ages, Apgar scores, frequency of pharmacologic blood pressure support, and umbilical artery catheter). Postnatally, the respiratory status of indomethacin-treated infants was not significantly different from controls when comparing mean number of days on the ventilator and the number of infants with chronic lung disease at 28 days of life. In contrast, EDP-treated infants had improved respiratory status compared with controls. At UWMC, ELBW infants are routinely extubated to nasal continuous positive airway pressure (CPAP), and this could have resulted in earlier administration of CPAP to EDP-treated infants. Four of the six EDP-treated infants who developed FSBP were exposed to nasal CPAP before the time of their perforation. Other potentially confounding therapeutic agents, betamethasone and caffeine, were similar between all cohorts. Caffeine is the only methylxanthine used at the UWMC NICU. Ranitidine, another potentially confounding therapeutic agent, was universally administered in the hyperalimentation to all patients in the study.
There were nine cases of ELBW infants with pneumoperitoneum during the 13-month period of the study. All of these patients were treated surgically. One infant had trisomy 21, was critically ill, had multifocal areas of necrotic bowel, and was diagnosed with NEC by both the surgeon and pathologist of record. The remaining eight had pneumoperitoneum identified in otherwise stable infants whose blood cultures failed to grow a pathogen. Four of the infants were still NPO, two were receiving trophic enteral feeds, and two were having their enteral feeds advanced when the pneumoperitoneums occurred. The average age at time of surgery was 7.13 days (Ϯ 2.80 SD) after birth. Operative findings demonstrated a single, focal perforation located near the mesentery of the ileum in all except one case, in which a solitary lesion occurred in the jejunum (Figure 1) . After surgery, all eight infants progressed to full enteral feeds without additional surgical intervention.
Microscopic examination of tissue obtained from bowel resection revealed multiple sites of segmental muscle degeneration and segmental absence of the muscularis externa around the site of perforation ( Figure 2 ). There was no lymphangiectasia, minimal submucosal edema, and minimal to mild inflammation consisting primarily of histiocytes in the regions of vacuolar degeneration. The surrounding mucosa and underlying muscularis mucosa were intact in all cases (Figure 2 ). Fungal stains revealed no evidence of fungus in the bowel sections (data not shown).
The prevalence of gastrointestinal disease, including FSBP and pneumoperitoneum, was significantly higher in infants receiving EDP compared with controls but was not different between indomethacintreated and untreated infants (Table 1) . There was an increased trend for FSBP in infants who received both EDP and indomethacin (four of six infants (66%)), but this subgroup was too small for valid analysis. Relative risk was calculated for both EDP and indomethacin (Table  2 ). There was no increased risk for FSBP with indomethacin; however, there was a 12.3-fold greater risk for FSBP with EDP.
DISCUSSION
Previous case reports have associated FSBP with obstructive-ischemic injury, 2,3 congenital absence of the muscularis externa, 4 -6 candidal infection, 11 indomethacin, 7, 8 and dexamethasone. 9, 10 Several of these possibilities were excluded in our patient group. Operative findings in our patients with FSBP revealed no obstructions and were inconsistent with ischemic injury, because most lesions were not contiguous with the antimesenteric portion of the bowel in which embolic or ischemic events are expected. Furthermore, the surrounding bowel was considered sufficiently healthy for primary anastamosis in five of eight cases at the time of laparotomy. Because all available pathology specimens had segments of degeneration coincident with segments of absent muscle, congenital segmental absence of the muscularis externa was felt to be unlikely. In addition, a large clustering of infants with congenital segmental absence of the muscularis externa would be unusual. Instead, FSBP appears to result from segmental degeneration of the muscularis externa in this patient population. Because all infants Ineligible for early dexamethasone 0.00 0.00 0.00 *Average days on the ventilator were tallied as days on the ventilator until successful extubation; however, two infants died on the ventilator at 40 and 42 days of life. These were included as days on the ventilator until death. **Statistically significant difference at a p value of Յ0.05. ***Statistically significant difference at a p value of Յ0.01.
with FSBP failed to grow a pathogen from their blood cultures and there was no evidence of fungus in the available pathologic specimens, both bacterial and fungal etiologies are also unlikely. From the list of risk factors derived from case reports of FSBP above, only indomethacin and dexamethasone could not be excluded by intraoperative, microbiologic, or pathologic findings. Indomethacin is the only agent implicated in the genesis of FSBP 7, 8 that also has been proven to cause intestinal injury in animal models. 12, 13 Despite this, we were unable to demonstrate an increased risk for FSBP in infants treated with indomethacin. In contrast, there was a 12-fold increase in the risk of FSBP with EDP. This degree of risk strongly suggests a causal relationship between dexamethasone and FSBP.
The mechanism by which dexamethasone might induce FSBP is unknown. Our microscopic findings suggest a perturbation of normal development in which the ileal mucosa is thickened while the sur- Figure 1 . Two intra-operative photographs of focal ileal perforation in ELBW infants who received early postnatal dexamethasone. A, The arrow points to an isolated perforation, and the arrowhead touches on the mesenteric border to demonstrate the close proximity of this lesion. The surrounding gut is free of discoloration consistent with healthy bowel. B, The arrow points to an isolated perforation at the edge of the mesentery (which is stained by meconium). The surrounding bowel appears unaffected. Original magnification is ϫ25. B, Segment of ileum demonstrating nuclear pyknosis, lack of inflammation, and fiber shrinkage (arrows) in the external layer of muscle while the inner layer is spared. Original magnification is ϫ250. C, Higher power magnification of A demonstrating lack of inflammation and sharp demarcation of muscle loss resembling "congenital absence" (arrows). Original magnification is ϫ100. D, Segment of ileum in which both layers of the muscularis propria are undergoing degeneration without inflammation. There is vacuolar change in the outer layer (small arrow) with disappearance and degeneration of the inner layer (large arrow). Original magnification is ϫ250.
rounding muscularis externa is thinned and degenerated in focal areas. In support of these mucosal changes are reports that steroids accelerate maturation of the mucosa in rats 14 and reduce the incidence of NEC in premature infants and in rat pups by enhancing mucosal barrier function. 15, 16 In support of smooth muscle developmental perturbation is a report that dexamethasone alters collagen and collagenase mRNA expression in human intestinal smooth muscle cells 17 and collagen expression in rat small intestine. 14 The developmental effects of dexamethasone might also be compounded by other agents that affect cell signaling or second messenger function, such as indomethacin, caffeine, betamethasone, or ranitidine. Likewise, both nasal CPAP and enteral feeding can result in bowel distention that could precipitate FSBP when the bowel wall has been rendered vulnerable.
Based on our findings, EDP poses a significant risk to the ELBW infant. The potential for FSBP should be factored into the risk-benefit analysis when considering EDP. Because the safety and efficacy of EDP is currently being scrutinized by prospective multicenter trials, we suggest that centers employing this experimental strategy provide parental notification about FSBP as a potential adverse outcome of EDP. Finally, centers using EDP should closely monitor for pneumoperitoneum while treating ELBW infants with dexamethasone. Early detection may improve the morbidity of FSBP by facilitating rapid surgical correction.
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Author's Addendum During revision, we note the publication of a relevant prospective trial (Garland JS, Alex CP, Pauly TH, et al. A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics 1999;104:91-99). EDP was associated with a significant risk for FSBP during the first week of life in ELBW infants. The risk was also independent of indomethacin exposure in their study. 
